Sonmezer Meliha Cagla, Dizman Gulcin Telli, Erul Enes, Sahin Taha Koray, Saricaoglu Tuğba, Alp Alparslan, Tanriover Mine Durusu, Uzun Omrum, Unal Serhat, Akova Murat
Infectious Diseases and Clinical Microbiology Department, Hacettepe University Faculty of Medicine, 06100 Ankara, Turkey.
Internal Medicine Department, Hacettepe University Faculty of Medicine, 06100 Ankara, Turkey.
Vaccines (Basel). 2022 Jul 18;10(7):1140. doi: 10.3390/vaccines10071140.
Coronavirus disease 2019 (COVID-19) continues to pose a threat to public health with the potential for the emergence of new variants. Vaccines are the milestones to control and slow down the damage of the pandemic. As of January 2021, a two-dose regimen with CoronaVac was authorized in Turkey. Due to the waning seroprevalence rate of SARS-CoV-2 over time, BNT162b2 or CoronaVac has been administered as the third dose following a two-dose CoronaVac regimen as a national vaccination policy. As of 14 January 2021, 5243 volunteers who received two doses of the CoronaVac vaccine at Hacettepe University Adult Vaccine Center were followed prospectively. In our study, relative vaccine effectiveness (VE) for the third dose of the CoronaVac was 58.24% and 87.27% for BNT162b2 in preventing symptomatic COVID-19 cases. There were no hospitalizations, intensive care unit admissions, or deaths in third-dose booster groups with either BNT162b2 or CoronaVac, yielding 100% effectiveness. Both homologous or heterologous third-dose boosters provided further protection against severe COVID-19 and should be prioritized as an effective strategy to combat the COVID-19 pandemic.
2019冠状病毒病（COVID-19）继续对公众健康构成威胁，有可能出现新的变种。疫苗是控制和减缓大流行危害的里程碑。截至2021年1月，土耳其批准了两剂科兴疫苗的接种方案。由于随着时间推移，严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的血清流行率逐渐下降，作为国家疫苗接种政策，在两剂科兴疫苗接种方案之后，已接种BNT162b2或科兴疫苗作为第三剂。截至2021年1月14日，对在哈杰泰佩大学成人疫苗中心接种两剂科兴疫苗的5243名志愿者进行了前瞻性随访。在我们的研究中，第三剂科兴疫苗预防有症状COVID-19病例的相对疫苗效力（VE）为58.24%，BNT162b2为87.27%。使用BNT162b2或科兴疫苗的第三剂加强针组均未出现住院、重症监护病房收治或死亡情况，效力达100%。同源或异源第三剂加强针均能进一步预防重症COVID-19，应作为对抗COVID-19大流行的有效策略予以优先考虑。
